First Novartis started their high throughput screening campaign, then Roche signed a licensing agreement for PTC Therapeutics' SMA programme and then at the start of 2012 another largish pharmaceutical company decided to tag along.
Biogen Idec and ISIS Pharmaceuticals announced a global collaboration on ISIS-SMNRx drug.
Under the terms of the agreement, Isis will receive an upfront payment of$29 million and is eligible to receive up to $45 million in milestone payments associated with the clinical development of ISIS-SMNRx prior to licensing.
Three large players are now competing to be the first to bring SMA treatment to the market.
Good news? We sure hope so!
Biogen Idec and ISIS Pharmaceuticals announced a global collaboration on ISIS-SMNRx drug.
Under the terms of the agreement, Isis will receive an upfront payment of
Three large players are now competing to be the first to bring SMA treatment to the market.
Good news? We sure hope so!
Comments
Post a Comment